ARCA BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA ON GENCARO DEVELOPMENT FOR ATRIAL FIBRILLATION

End of Phase 2 FDA meeting - FINAL